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Abstract
Despite availability of annual influenza vaccines, influenza causes significant morbidity and mortality in the elderly.
This is at least in part a result of immunosenescence; the age-dependent decrease in immunological competence
that results in greater susceptibility to infections and reduced responses to vaccination. To improve protective immune
responses in this age group, new vaccines strategies, such as the use of adjuvants, are needed. Here, we evaluated the
mucosal vaccine adjuvant Endocine™, formulated with split influenza antigen and administered intranasally in aged
(20-month old) mice. Humoral immune responses were assessed and compared to unadjuvanted intranasal and
subcutaneous vaccines. We show that formulation with Endocine™ significantly enhances hemagglutination inhibition
(HI) titers, as well as serum IgG and mucosal IgA antibody titers, compared to both types of unadjuvanted vaccines.
Thus, our results indicate that intranasal vaccination with Endocine™ is a possible approach for the development of
mucosal influenza vaccines for the elderly.
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Introduction
Worldwide, annual influenza epidemics are estimated to
result in 250 000 to 500 000 deaths and up to 5 million
cases of severe illness [1]. Adults 65 years of age and
older are particularly vulnerable to complications from
influenza infection, and account for 90% of all influenza-
associated deaths in the U.S. [2]. Vaccination is the pri-
mary strategy to prevent and reduce morbidity and
mortality associated with influenza [3], and the World
Health Organization (WHO) recommends annual vaccin-
ation for groups at high risk of complications, including
the elderly, young children, pregnant women, health-care
workers, and individuals with underlying medical condi-
tions [1]. However, it has proven difficult to stimulate po-
tent immune responses in elderly individuals, and studies
in mice, ferrets and humans show that antigen-specific
immune responses decline with age [4–9]. Accordingly, a
quantitative review by Goodwin et al. shows that the
clinical vaccine efficacy of injectable influenza vaccines
was 17–53% in the elderly [10] compared to 70–90% in
younger adults [11], and that following influenza vac-
cination, younger adults had up to 4 times higher anti-
body levels compared with older adults [10].
Strategies to augment the immune response in older
adults include using alternative routes of vaccine de-
livery, a higher dose of antigen, or addition of an
adjuvant. The Fluzone® High-Dose influenza vaccine
(Sanofi Pasteur Inc.) was designed for people 65 years
and older, and contains four times the amount of
hemagglutinin (HA) contained in standard-dose vaccines
[12, 13]. The adjuvanted injectable influenza vaccine
Fluad® was developed (by Novartis) for older adults.
Both Fluzone® High-Dose and Fluad® have demonstrated
enhanced humoral immune responses compared to
standard-dose non-adjuvanted vaccines [12–15]. Never-
theless, immunization advisory committees such as the
Advisory Committee on Immunization Practices (ACIP)
in the U.S., and the National Advisory Committee on
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Immunization (NACI) in Canada, consider that there is
currently insufficient evidence to make a recommendation
for their routine use in the elderly population. There is
currently only one intranasal influenza vaccine on the
western market, which is a live attenuated influenza
vaccine (LAIV) called Fluenz®/Flumist® (MedImmune,
AstraZeneca). However, LAIV is not licensed for adults
>18 years in Europe, and not recommended for indi-
viduals ≥50 years in the U.S. It has been speculated
that LAIV’s limited efficacy in adults and elderly could
be due to its inability to infect individuals with pre-
existing immunity [16–18]. Following vaccination with
LAIV, viral shedding can occur and there is a possibility
that the vaccine strain is transmitted [19], which could be
problematic if LAIV recipients come into contact with se-
verely immunocompromised persons.
Here we sought to evaluate a vaccine based on split in-
fluenza antigen together with the lipid-based adjuvant
Endocine™ in aged mice. Endocine™ is a mucosal adju-
vant that has been shown to be safe and well tolerated
in both pre-clinical and clinical studies [20–24]. We have
previously demonstrated that vaccines formulated with
Endocine™ enhance both humoral and cell-mediated im-
mune responses in mice after intranasal vaccination [20],
and a study in ferrets demonstrated that Endocine™ in-
duces high HI and virus neutralization titers, and fully
protects ferrets from virus replication in the lungs [22].
Furthermore, a recent study by Falkeborn et al. showed
that an Endocine™-adjuvanted influenza vaccine evoked
serum IgG and virus neutralization titers to comparable
levels as cholera toxin (CT) in mice, and induced signifi-
cantly higher serum and mucosal influenza-specific IgA
titers than an alum-adjuvanted vaccine administered par-
enterally [25]. In the current study we tested if Endocine™
could enhance systemic and mucosal humoral immune
responses to influenza antigen in aged mice.
Materials and methods
Mice
Female BALB/c mice were purchased from Charles
River, Germany and used for vaccinations at 2 or 20
months of age. All animal experiments were approved
by the regional animal experimental ethics committee in
Stockholm (North), Sweden. The study was performed
in accordance with institutional guidelines at Adlego
Biomedical AB, Stockholm, Sweden.
Antigen and adjuvant
All mice were vaccinated with A/California/07/
2009(H1N1)pdm split influenza antigen from season
2012/2013 (kindly provided by Mitsubishi Tanabe
Pharma Corporation, Kanagawa, Japan) with or with-
out the adjuvant Endocine™ (Eurocine Vaccines AB,
Stockholm, Sweden), except the control groups which
received saline. The adjuvant Endocine™ consists of
the lipids mono-olein and oleic acid [21, 22, 24].
Vaccination and sampling
Mice (n = 8-11 per group) received 3 μg HA +/- 2%
Endocine™ intranasally in 5 μL/nostril, or 50 μL of 3 μg
HA subcutaneously in one hind leg. During vaccination,
the mice were anaesthetized with isoflurane (IsoFlo® vet,
Orion Pharma Animal Health, Sollentuna, Sweden). The
mice were immunized three times at three-week inter-
vals (day 0, 21 and 42). Blood samples and nasal lavages
were collected one day before each immunization and
three weeks after the last immunization at termination.
The samples were stored at -20 °C until analysis. After
sacrifice, the lungs were removed, put in PBS and frozen
at -70 °C.
Determination of influenza-specific antibodies by ELISA
All serum samples were analyzed individually for influenza
specific IgG, IgA, and subclass IgG (IgG1, IgG2a) with an
enzyme-linked immunosorbent assay (ELISA). The sam-
ples were tested against the trivalent split vaccine Inflexal
from season 2012/2013 (Cruzell, Madrid, Spain), consist-
ing of A/California/07/2009 (H1N1), A/Victoria/361/2001
(H3N2) and B/Wisconsin/1/2010 influenza strains. Sero-
logical responses were measured as previously described
[20] with the exception that the plates were coated with
Inflexal at a concentration of 1.5 μg HA/mL. Nasal lavage
was also analyzed for nasal IgA against Inflexal. These
samples were incubated overnight in +4 °C on the plate
and then analyzed as previously described [20]. The lungs
were homogenized, flushed with PBS and the solution was
collected and centrifuged to remove tissue and cell debris.
To analyze total IgA, plates were coated with 1 μg/mL of
Goat-anti mouse IgA (MyBiosource.com). The samples
were then incubated overnight in +4 °C on the plate. To
detect total IgA, Mouse Immunoglobulins AP (DAKO)
diluted 1:3,000 and p-nitrophenyl phosphate (pNPP)
(Sigma-Aldrich) were used. To analyze influenza spe-
cific IgA and IgG in lung homogenate, plates were
coated with Inflexal and analyzed as previously de-
scribed [20].
Hemagglutination inhibition (HI)
Samples were pooled in each group from each time point
except serum samples from day 63 which were analysed
individually. Sera were tested in hemagglutination inhibi-
tion (HI) as previously described [26] against pH1N1 A/
California/07/09 virus at Viroclinics Biosciences B.V.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(La Jolla, CA, US). Analysis of immunological parameters
was performed using Kruskal-Wallis one-way ANOVA.
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When significant, Mann-Whitney U-test was applied for
comparison between two groups. A p-value of <0.05 was
considered statistically significant.
Results and Discussion
Intranasal delivery of an Endocine™-formulated influenza
vaccine enhances HI and IgG titers in aged mice
Several studies have shown that by using adjuvanted vac-
cines in old mice, it is possible to stimulate a higher and
more protective antibody response compared to non-
adjuvanted vaccines [27–30]. Previous publications re-
garding immunization with the adjuvant Endocine™ in 2
month old mice have shown significantly increased
humoral and cell-mediated immune response compared
to non-adjuvanted influenza vaccine given intranasally
[20, 21, 25]. To assess the humoral immune response in
aged mice, we immunized 20-month old mice intranasally
with antigen from the A/California/07/2009(H1N1)pdm
strain formulated with or without Endocine™. In addition,
both aged and young (2-month old) mice were subcutane-
ously immunized with unadjuvanted influenza antigen. As
expected, HI titers were considerably greater in young
mice compared to old mice among the subcutaneously
immunized mice (Fig. 1a and b). Interestingly, addition of
Endocine™ to the intranasally-administered vaccine signifi-
cantly enhanced HI titers in aged mice (Fig. 1a and b).
Furthermore, among the aged mice, we found that
those vaccinated intranasally with the Endocine™-
adjuvanted vaccine had significantly higher HI titers
than mice vaccinated subcutaneously without adju-
vant (Fig. 1a and b).
When serum IgG titers were evaluated in aged mice,
we found that the Endocine™-vaccinated mice responded
with significantly higher IgG and IgG1 titers than mice
vaccinated intranasally without adjuvant (Fig. 2a and b),
in accordance to what has previously been demonstrated
in young mice [20, 21, 25]. Subcutaneously vaccinated
aged mice had higher serum IgG levels than Endocine™-
vaccinated mice after the first dose. Nevertheless, we
noted that the Endocine™-vaccinated aged mice exhibi-
ted higher IgG titers after the second and third dose
(Fig. 2a and b), indicating that two intranasal vaccine
doses are needed to achieve full effect. We speculate that
two vaccine doses in influenza-naïve individuals may
correspond to one vaccine dose in the adult population
which have pre-existing immunity against influenza vi-
ruses. In earlier studies [20] and unpublished data using
2 month old BALB/c mice, the IgG2a titers were lower
than IgG1 titers. Therefore, it was expected that the
IgG2a levels would be low in this study, especially since
aged mice have an impaired activation of immune cells
connected to the adaptive immune response [31, 32]. In
a study by Higgins et al. [27], lower levels of IgG2a were
also detected in aged mice compared to young mice
after influenza vaccination with adjuvant. Furthermore,
in a study of healthy adults aged <40 (young), 40–64
(middle-aged) and ≥65 (elderly) years, it was reported
that aging was associated with a significant impairment
of IgG1 antibody production (corresponds to IgG2a in
mice) [33].
Analysis of influenza-specific IgG in lung homogenates
of aged mice revealed that the Endocine™-adjuvanted
vaccine generated significantly higher antibody titers
than the unadjuvanted intranasal vaccine (Fig. 2c). Over-
all, our results demonstrate that intranasal delivery of an
Endocine™-formulated influenza vaccine can improve
vaccine immunogenicity and help overcome the limita-
tions of immunosenescence.
Fig. 1 Evaluation of HI response. Mice were vaccinated intranasally or subcutaneously three times with three week intervals using split influenza
antigen (A/California/07/2009(H1N1)pdm) formulated with or without the adjuvant Endocine™. a Individual HI titers (GMT) at day 63 and (b) HI titers
(median) over time. Significant differences to the adjuvanted vaccine group is indicated by *p < 0.05, **p < 0.01, ***p < 0.001
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Endocine™ boosts influenza-specific mucosal IgA titers in
aged mice
In addition to a systemic immune response, influenza
vaccines should optimally induce a mucosal immune re-
sponse in the respiratory tract. We found no influenza-
specific nasal IgA in subcutaneously vaccinated mice,
neither in young nor aged mice. By contrast, intranasal
vaccination of aged mice potently induced influenza-
specific nasal IgA (Fig. 3a). Although not statistically sig-
nificant, and not to the same extent as previously seen
in young mice [20, 25] and unpublished data, formula-
tion with Endocine™ somewhat enhanced the IgA titers
(Fig. 3a). Endocine™-vaccinated mice responded with 2.4
times higher geometric mean titer than mice immunized
intranasally without adjuvant (GMT of 77 and 32, re-
spectively). Interestingly, a study by Asanuma et al.
showed that influenza virus colonization was totally pre-
vented in the presence of virus-specific S-IgA antibody
response in aged mice, despite their reduced levels of
IgG [34].
Fig. 2 Evaluation of influenza-specific IgG responses. Mice were vaccinated intranasally or subcutaneously three times with three week intervals
using split influenza antigen (A/California/07/2009(H1N1)pdm) formulated with or without the adjuvant Endocine™. Influenza-specific (a) serum
IgG, IgG1 and IgG2a endpoint titers (GMT ± CI95), (b) serum IgG titer (median) over time and (c) IgG titers (GMT) in lung homogenates are shown.
Significant differences to the adjuvanted vaccine group is indicated by *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 3 Evaluation of influenza-specific IgA response. Mice were vaccinated intranasally or subcutaneously three times with three week-interval
using split influenza antigen (A/California/07/2009(H1N1)pdm) with or without the adjuvant Endocine™. Influenza-specific IgA (a) in nasal wash
and (b) lung homogenate. c Total IgA in lung homogenate. Data shown represent geometric mean titers (GMT). For data which included values
of 0 (1 mouse in the non-adj s.c. 20 month group, and 2 mice in the non-adj s.c. 2 month group), a value of 0.01 was added to calculate GMT.
Significant differences to the adjuvanted vaccine group is indicated by *p < 0.05, **p < 0.01, ***p < 0.001
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Influenza-specific IgA levels were substantially lower
in lung homogenates than in nasal washes, nevertheless,
Endocine™-vaccinated mice had significantly higher IgA
titers compared to mice immunized intranasally or sub-
cutaneously without adjuvant (Fig. 3b). The total amount
of IgA antibodies, not only influenza-specific, was simi-
lar in all groups of aged mice, whereas significantly
lower levels were detected in the group with young mice
(Fig. 3c). This is not completely unexpected, as previous
analyses have shown a similar difference in IgA levels
between young and older mice in gut tissue [35, 36].
Interestingly, even though the frequency of local muco-
sal B cells in gut tissue is reduced in elderly mice, the
synthesis and secretion of immunoglobulins was shown to
be higher in older mice compared to young mice [35].
Taken together, these data indicate that intranasal adminis-
tration of influenza vaccine adjuvanted with Endocine™
may have advantages over parenteral immunization due to
its ability to induce mucosal IgA.
In this study, challenge was not performed, however, a
previous study in young mice vaccinated intranasally
with influenza and Endocine™ did show reduced levels of
viral RNA in the lungs [21]. Furthermore, immunization
of 12 month old ferrets with influenza vaccine adju-
vanted with Endocine™ induced a broad antibody re-
sponse and fully protected the animals after challenge
with influenza virus [22]. Future studies should explore
whether intranasal immunization with Endocine™ con-
fers protection against influenza challenge in aged mice.
The current study is one of few to evaluate the
humoral systemic and mucosal immune responses to in-
fluenza vaccination in 20-month old mice. We show that
it is possible to improve the immune response to an
inactivated intranasal vaccine by formulating the vaccine
with Endocine™. In addition, the intranasal Endocine™-
adjuvanted influenza vaccine improved immune re-
sponses (HI titers, serum IgG and mucosal IgA) in aged
mice compared to a non-adjuvanted parenteral vaccine.
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